Prospective Data Collection

Benefits of VQI data collection

✓ Elimination of site contracting, training, monitoring and IRB approval costs, due to existing SVS PSO contract with sites and existing system for data entry at VQI sites
✓ Ability to specify your own custom variables and time points
✓ More rapid, consecutive patient accrual, since consent is not required to collect data for quality improvement projects within the SVS PSO
✓ Efficient and low-cost data capture since the majority of data are already collected in VQI
✓ Real-world data from multiple sized centers across the U.S. supports the potential to broaden indications for use
✓ Evaluate the real-world application of devices beyond the scope of expert centers
✓ Registry data from the SVS PSO is accepted by the FDA as high quality for required post approval studies
✓ Potential to reduce requisite number of patients due to availability of control group within VQI

OVERVIEW
Because of its collection of real world data involving implantable devices for vascular treatment, the VQI is uniquely positioned to provide valuable information to your vascular device R&D, marketing and project teams.
Data Sharing through the VQI offers you an opportunity to understand device performance in specific patient groups based on key demographics, procedure outcomes and follow up. Outcome data can be risk-adjusted by the SVS PSO when needed.
Pricing is based on volume of data shared. All data are de-identified for patient, hospital and provider.

THE VQI PROGRAM
Governed by the SVS PSO, the Data Sharing program is designed to provide industry partners with information to better design and improve vascular devices while ensuring appropriate protection of the data.
Data are validated, benchmarked, and provided as de-identified, blinded data sets, and available for both venous and arterial procedures
New data are available each month for all procedures.
Scope of Project

Industry sponsors may submit specific and customized data collection requests for studies including:

- Prospective observational studies of device performance
- Randomized controlled trials of new devices
- FDA required post approval studies of recently approved devices
- Potential for investigational device exemption studies of new devices

ADDED DATA FOR ANALYSIS

Retrospective Data Sharing
- Retrospective data analysis to improve product
- Market research to define patient selection in current practice
- Real world outcomes to validate performance and aid development

SERVICES AVAILABLE

Data Sharing
Custom Reports
Custom Variables
Data for Post-Approval Studies
Data for Pre-Market Studies

CONTACT
For more information on our Data Sharing portfolio, please contact Meridith Mitchell at 603.738.0066 or email mitchell@m2s.com